Abstract: A private network is disclosed as having an HA (high availability) cluster and a VRRP (Virtual Router Redundancy Protocol) router for each of several nodes within the HA cluster. The VRPP router tracks each worker node in the cluster and provides a reliable service that run on the cluster of nodes. Track worker nodes are closely tracked using the VRRP router for each node. Node failures are immediately acted upon. In addition, a load balancer layer allows the amount of resources being used at any particular time to be balanced between the different nodes in the cluster.

Abstract: A method and apparatus for utilizing microslices in an enterprise wireless communication network to manage and control network performance. The microslice instances are monitored during network operation, for example at communication nodes, functional blocks, and end-to-end to provide Key Performance Indicators (KPIs). These KPI are compared with performance objectives, which may be Service Level Objectives (SLOs). If the performance objectives are not met by the KPIs, then one or more of the microslice instances may be dynamically adjusted until the performance objectives are sufficiently met. Alternatively, the lower priority microslice instances may be dropped (i.e., terminated) until the performance objectives are sufficiently met.

Abstract: A method and apparatus for defining, configuring, operating, monitoring, and modifying microslices in an enterprise network is described. Microslices provide an end-to-end logical network through multiple networks, which allows efficient arrangement of data flows in the enterprise network with a defined Quality of Service (QoS). Various embodiments of a system for creating and implementing microslice instances in a wireless communications network are disclosed. A microslice instance can connect a UE in the enterprise network with an external server. In some embodiments, the enterprise network administrator can define Service Level Objectives (SLOs), device groups, service types, and user application groups, and associate them with one or more microslices. An orchestrator can configure the microslice with an appropriate amount of network resources to be allocated to the microslice, and then set-up, operate, monitor, and modify the microslice instance to adapt to current network conditions.

Abstract: A centralized Internet of Things (IoT) manager of an IoT system is configured generate and deploy a data pipeline application to an edge system. The centralized IoT manager is configured to receive a request for a data category and identification of a data transformation function, identify a data source of the IoT system belonging to the data category, and identify an edge system of the IoT system associated with the data source. The centralized IoT manager is further configured to generate a containerized data pipeline application based on a configuration of the edge system that is configured apply the data transformation function to input data to provide transformed data, and provide the containerized data pipeline application to the edge system.

Abstract: A centralized Internet of Things (IoT) manager of an IoT system is configured generate and deploy a data pipeline application to an edge system. The centralized IoT manager is configured to receive a request for a data category and identification of a data transformation function, identify a data source of the IoT system belonging to the data category, and identify an edge system of the IoT system associated with the data source. The centralized IoT manger is further configured to generate a containerized data pipeline application based on a configuration of the edge system that is configured apply the data transformation function to input data to provide transformed data, and provide the containerized data pipeline application to the edge system.

Abstract: A centralized Internet of Things (IoT) manager of an IoT system is configured generate and deploy a data pipeline application to an edge system. The centralized IoT manager is configured to receive a request for a data category and identification of a data transformation function, identify a data source of the IoT system belonging to the data category, and identify an edge system of the IoT system associated with the data source. The centralized IoT manger is further configured to generate a containerized data pipeline application based on a configuration of the edge system that is configured apply the data transformation function to input data to provide transformed data, and provide the containerized data pipeline application to the edge system.

Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Abstract: The present application relates to novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

Abstract: The present application relates to novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

Abstract: The present application relates to novel 5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to prodrugs, derivatives, polymorphs, pharmaceutically acceptable salts and compositions comprising the said novel 5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine compounds and their derivatives and their use in the treatment of various disorders.

Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.